EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Canbridge Pharmaceuticals's Enterprise Value is HK$158.8 Mil.
Canbridge Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-349.0 Mil. Therefore, Canbridge Pharmaceuticals's EV-to-FCF for today is -0.46.
The historical rank and industry rank for Canbridge Pharmaceuticals's EV-to-FCF or its related term are showing as below:
HKSE:01228'
s EV-to-FCF Range Over the Past 10 Years
Min: -9.56 Med: -0.45 Max: 0.91
Current: -0.47
During the past 5 years, the highest EV-to-FCF of Canbridge Pharmaceuticals was 0.91. The lowest was -9.56. And the median was -0.45.
HKSE:01228's EV-to-FCF is ranked worse than 100% of 378
companies
in the Biotechnology industry
Industry Median: 8.345
vs HKSE:01228: -0.47
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Canbridge Pharmaceuticals's EV-to-FCF
For the Biotechnology subindustry, Canbridge Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Canbridge Pharmaceuticals's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Canbridge Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Canbridge Pharmaceuticals's EV-to-FCF falls into.
Canbridge Pharmaceuticals's current Enterprise Value is HK$158.8 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Canbridge Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-349.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Canbridge Pharmaceuticals's PE Ratio for today is calculated as:
Canbridge Pharmaceuticals's share price for today is HK$0.34.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Canbridge Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.974.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Canbridge Pharmaceuticals EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Canbridge Pharmaceuticals's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Canbridge Pharmaceuticals (HKSE:01228) Business Description
Canbridge Pharmaceuticals Inc is a global biopharmaceutical company. It is committed to the research, development, and commercialization of biotech therapies targeting rare diseases and rare oncology. The company's core product in the rare oncology area CAN008, is a glycosylated CD95-Fc fusion protein being developed for the treatment of glioblastoma multiforme (GBM). In the rare disease area, the company have seven biologics and small molecules products and product candidates for the treatment of Hunter Syndrome (MPS II) and other lysosomal storage disorders (LSDs), complement mediated disorders, hemophilia A, metabolic disorders, and rare cholestatic liver diseases including ALGS, PFIC and BA. Its pipeline consists of biologics, small molecules, and gene therapy solutions and 13 drugs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01228 has been successfully added to your 